The ADME assay development pipeline includes in vitro ADME assays that are necessary once a lead candidate has been selected. The safety profile of a drug candidate will depend partly on its interactions with other drugs, especially those that may be administered concomitantly in standard-of-care treatment. Assessing the risks of possible drug-interactions using validated bioanalytical methods is thus an essential early step in the candidate development process. Q2 Solutions offers a suite of in vitro assays to support drug-drug interaction testing, including cytochrome P450 (CYP) enzyme inhibition (IC50), time-dependent CYP inhibition, induction of CYP enzymes, and CYP reaction phenotyping. All in vitro metabolism assay results are presented in fully QC-reviewed, regulatory-style reports to support filing of IND applications.
Speaker - Oswaldo A Lozoya, PhD, Genomics Staff Scientist - TSAIL, Q2 Solutions As part of the Machine Learning and Single Cell Genomics in Public Health session, Oswaldo presents insights,...
The glomerular filtration rate (GFR) is a critical indicator of kidney function, and its value may be measured using a simple blood test for creatinine. Historically, studies have shown that people...
As a leading laboratory services organization for trials across the globe, we integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your...